RESUMO
Clinical and most often moderate skeletal muscle involvement is a frequent problem in adults with hypothyroidism, and includes a number of different manifestations. Severe involvement with rhabdomyolysis, however, is very rare, and only a few cases have been reported to date, most of them with an additional factor of muscle injury. We described a patient with stage 3 chronic kidney disease who presented with rhabdomyolysis while taking fenofibrate, and was found to have hypothyroidism. We also highlighted the importance of excluding the diagnosis of thyroid dysfunction before treatment with lipid-lowering agents.
Assuntos
Fenofibrato/efeitos adversos , Hipolipemiantes/efeitos adversos , Hipotireoidismo/complicações , Insuficiência Renal Crônica/complicações , Rabdomiólise/induzido quimicamente , Humanos , Hipertrigliceridemia/tratamento farmacológico , Masculino , Pessoa de Meia-IdadeRESUMO
Clinical and most often moderate skeletal muscle involvement is a frequent problem in adults with hypothyroidism, and includes a number of different manifestations. Severe involvement with rhabdomyolysis, however, is very rare, and only a few cases have been reported to date, most of them with an additional factor of muscle injury. We described a patient with stage 3 chronic kidney disease who presented with rhabdomyolysis while taking fenofibrate, and was found to have hypothyroidism. We also highlighted the importance of excluding the diagnosis of thyroid dysfunction before treatment with lipid-lowering agents.
Manifestações musculoesqueléticas variadas e de moderada intensidade são comuns em adultos com hipotireoidismo. No entanto, o envolvimento muscular grave, caracterizado por rabdomiólise, é incomum. Até o momento, poucos casos foram descritos na literatura, e a maior parte deles em associação com um fator adicional de dano muscular. Descrevemos um paciente com doença renal crônica (estádio 3) que se apresentou com rabdomiólise durante o tratamento com fenofibrato e cuja investigação adicional evidenciou hipotireoidismo primário. Enfatizamos, ainda, a importância da exclusão de disfunção tireoidiana antes de iniciar terapia com agentes hipolipemiantes.
